On May 7, 2024, BioVersys AG closed the transaction. The company issued common shares for CHF 12.3 million in its third and final tranche, bringing a total funding of CHF 44.9 million in the transaction. The transaction included participation from new investor GSK plc.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1,774 GBX | -0.20% | -0.03% | +22.36% |
07:00am | US, European nations consider vaccinating workers exposed to bird flu | RE |
May. 24 | British Stocks Extend Losing Streak Amid Retail Sales Slump | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+22.36% | 92.24B | |
+38.51% | 727B | |
+31.74% | 599B | |
-6.23% | 354B | |
+18.78% | 328B | |
+1.35% | 277B | |
+16.00% | 243B | |
+8.41% | 205B | |
-5.93% | 203B | |
+6.19% | 164B |
- Stock Market
- Equities
- GSK Stock
- News GSK plc
- BioVersys AG announced that it has received CHF 44.9 million in funding from AMR Action Fund GP, LLC, GSK plc and other investor.